Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis
- 453 Downloads
Several fluoroquinolone antibiotics have been associated with cardiac adverse effects, leading to the withdrawal of some of these agents from the market. Cardiac side effects such as QT prolongation and torsades de pointes (TdP) have also been observed with fluoroquinolones currently on the market. In order to evaluate the cardiac risk of fluoroquinolones as a class, and the comparative risk for each individual drug, we conducted a systematic review, meta-analysis, and network meta-analysis.
MEDLINE, EMBASE and the Cochrane Library were searched, up to March 2018, for randomized controlled trials, cohort studies, and case–control studies that investigated the association between fluoroquinolone treatment and the risk of cardiovascular events and cardiovascular mortality. We followed the PRISMA 2009 guidelines for data selection and extraction. Outcomes were pooled using random effects models. Direct and indirect comparisons in network meta-analysis were performed using frequentist methods.
Thirteen studies were included in our analyses. Fluoroquinolone use was associated with a statistically significant 85% increase in the risk for arrhythmia (odds ratio [OR] 1.85; 95% confidence interval [CI] 1.22–2.81) and 71% increase in the risk for cardiovascular mortality (OR 1.71; 95% CI 1.39–2.09). Moxifloxacin ranked most likely to have the highest risk for arrhythmia (P-score 0.99) and for cardiovascular mortality (P-score 0.95) by network meta-analysis.
Our findings show a significant association between fluoroquinolone use and an increased risk for arrhythmia and cardiovascular mortality. Moxifloxacin ranked with the highest probability for cardiovascular adverse events. Further study is required to determine how to reduce the risk for fluoroquinolone-associated cardiac toxicity.
Compliance with Ethical Standards
Conflict of interest
Einat Gorelik, Reem Masarwa, Amichai Perlman, Victoria Rotshild, Momen Abbasi, Mordechai Muszkat, and Ilan Matok have no conflicts of interest that are directly relevant to the content of this study.
No sources of funding were used to assist in the preparation of this study.
- 1.emc. Ofloxacin SmCP [Internet]. https://www.medicines.org.uk/emc/product/8481/smpc. Accessed 9 May 2018.
- 11.Bolognesi M, Bolognesi D. Ciprofloxacin-induced paroxysmal atrial fibrillation. OA Case Rep (Internet). 2014;1–3. http://www.oapublishinglondon.com/images/article/pdf/1410967708.pdf. Accessed 8 May 2018.
- 13.Inghammar M, Svanström H, Melbye M, Pasternak B, Hviid A. Oral fluoroquinolone use and serious arrhythmia : bi-national cohort study. BMJ. 2016;352(i843):1–8.Google Scholar
- 16.Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos MPT. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses (Internet). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 2 Aug 2017.
- 18.Rücker G, Schwarzer G, Krahn U, König J. Netmeta: network meta-analysis using frequentist methods. 2017. https://cran.r-project.org/web/packages/netmeta/netmeta.pdf. Accessed 9 May 2018.
- 23.Zambon A, Polo Friz H, Contiero P, Corrao G. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case–control, case–crossover and case–time–control designs. Drug Saf (Internet). 2009;32(2):159–67.CrossRefGoogle Scholar
- 29.Monster TB, Johnsen SP, Olsen ML, Østergaard L, Friis S, McLaughlin JK, et al. Antibiotics and risk of first-time hospitalization for myocardial infarction: a population-based case–control study. Am J Ther (Internet). 2005;12(3):226–32.Google Scholar
- 30.Fink MP, Snydman DR, Niederman MS, Leeper KV, Johnson RH, Heard S, et al. Treatment of severe pneumonia in hospitalized patients : results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother. 1994;38(3):547–57.CrossRefGoogle Scholar
- 31.Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini GMU. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis (Internet). 2018;28(6):533–42.CrossRefGoogle Scholar
- 32.Inghammar M, Svanström H, Melbye M, Pasternak B, Hviid A. Oral fluoroquinolone use and serious arrhythmia : bi-national cohort study. BMJ (Internet). 2016;352(i843):1–8.Google Scholar
- 33.Zambon A, Polo Friz H, Contiero P, Corrao G. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case–control, case–crossover and case–time–control designs. Drug Saf. 2009;32(2):159–67.CrossRefGoogle Scholar